热门资讯> 正文

Spruce Biosciences GAAP每股收益为-6.68美元

2026-08-12 21:05

Spruce Biosciences(SPRB) 0

Spruce Biosciences press release (SPRB): Q2 GAAP EPS of -$6.68.
Cash and cash equivalents as of June 30, 2026 were $96.3 million, compared to $48.9 million as of December 31, 2025.
Spruce believes that its cash and cash equivalents as of June 30, 2026 will be sufficient to fund its planned operations and debt obligations into the second half of 2027.

More on Spruce Biosciences

Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy
Seeking Alpha’s Quant Rating on Spruce Biosciences
Historical earnings data for Spruce Biosciences
Financial information for Spruce Biosciences

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。